Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Gains from Sales and Divestitures (2025)

CG Oncology (CGON) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $7622.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $7622.0, compared with a TTM value of $7622.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $7622.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $7622.0 for Q4 2025 at CG Oncology.
  • Across five years, Gains from Sales and Divestitures topped out at $7622.0 in Q4 2025 and bottomed at $7622.0 in Q4 2025.